MC1R variants increase melanoma risk in families with CDKN2A mutations: A meta-analysis

Maria Concetta Fargnoli, Sara Gandini, Ketty Peris, Patrick Maisonneuve, Sara Raimondi

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Aim of the study: We performed a meta-analysis to assess whether MC1R variants increase the risk of melanoma in CDKN2A mutation carriers of melanoma-prone families. Methods: Data from 96 CDKN2A-positive melanoma-prone families from seven independent populations of Europe, United States and Australia were included in the analysis. Summary risk estimates were calculated by random-effect models. We explored between-study heterogeneity and publication bias. Association between MC1R variants and age at diagnosis was assessed by the non-parametric Wilcoxon test. Results: CDKN2A mutation carriers with ≥1 MC1R variant showed a double melanoma risk as compared to CDKN2A mutation carriers without MC1R variants (Summary OR; 95%CI: 2.2; 1.1-4.5). MC1R heterozygous subjects had no significantly higher melanoma risk than wild-type subjects (1.6; 0.5-5.4) while carriers of multiple MC1R variants had a more than four-times higher melanoma risk (4.6; 1.3-16.4). Carriers of red hair colour (RHC) variants showed an increased melanoma risk with a Summary OR of 3.5 (95%CI: 1.3-9.9). CDKN2A mutation carriers with MC1R variants had a statistically significant lower median age at melanoma diagnosis than CDKN2A mutation carriers with no MC1R variants (37 years versus 47 years, p-value <0.0001). Conclusion: MC1R variants significantly increase penetrance of CDKN2A mutations in melanoma-prone families, especially with respect to multiple MC1R variants and to RHC variants. A significant anticipation of melanoma diagnosis is observed in CDKN2A mutation carriers with MC1R variants.

Original languageEnglish
Pages (from-to)1413-1420
Number of pages8
JournalEuropean Journal of Cancer
Volume46
Issue number8
DOIs
Publication statusPublished - May 2010

Fingerprint

Meta-Analysis
Melanoma
Mutation
Hair Color
Publication Bias
Penetrance
Population

Keywords

  • Cyclin-dependent kinase inhibitor 2A
  • Familial melanoma
  • Genetic epidemiology
  • Melanocortin-1-receptor

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Medicine(all)

Cite this

MC1R variants increase melanoma risk in families with CDKN2A mutations : A meta-analysis. / Fargnoli, Maria Concetta; Gandini, Sara; Peris, Ketty; Maisonneuve, Patrick; Raimondi, Sara.

In: European Journal of Cancer, Vol. 46, No. 8, 05.2010, p. 1413-1420.

Research output: Contribution to journalArticle

@article{bad66bd2f7a74e5490191b7997fa6cf8,
title = "MC1R variants increase melanoma risk in families with CDKN2A mutations: A meta-analysis",
abstract = "Aim of the study: We performed a meta-analysis to assess whether MC1R variants increase the risk of melanoma in CDKN2A mutation carriers of melanoma-prone families. Methods: Data from 96 CDKN2A-positive melanoma-prone families from seven independent populations of Europe, United States and Australia were included in the analysis. Summary risk estimates were calculated by random-effect models. We explored between-study heterogeneity and publication bias. Association between MC1R variants and age at diagnosis was assessed by the non-parametric Wilcoxon test. Results: CDKN2A mutation carriers with ≥1 MC1R variant showed a double melanoma risk as compared to CDKN2A mutation carriers without MC1R variants (Summary OR; 95{\%}CI: 2.2; 1.1-4.5). MC1R heterozygous subjects had no significantly higher melanoma risk than wild-type subjects (1.6; 0.5-5.4) while carriers of multiple MC1R variants had a more than four-times higher melanoma risk (4.6; 1.3-16.4). Carriers of red hair colour (RHC) variants showed an increased melanoma risk with a Summary OR of 3.5 (95{\%}CI: 1.3-9.9). CDKN2A mutation carriers with MC1R variants had a statistically significant lower median age at melanoma diagnosis than CDKN2A mutation carriers with no MC1R variants (37 years versus 47 years, p-value <0.0001). Conclusion: MC1R variants significantly increase penetrance of CDKN2A mutations in melanoma-prone families, especially with respect to multiple MC1R variants and to RHC variants. A significant anticipation of melanoma diagnosis is observed in CDKN2A mutation carriers with MC1R variants.",
keywords = "Cyclin-dependent kinase inhibitor 2A, Familial melanoma, Genetic epidemiology, Melanocortin-1-receptor",
author = "Fargnoli, {Maria Concetta} and Sara Gandini and Ketty Peris and Patrick Maisonneuve and Sara Raimondi",
year = "2010",
month = "5",
doi = "10.1016/j.ejca.2010.01.027",
language = "English",
volume = "46",
pages = "1413--1420",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "8",

}

TY - JOUR

T1 - MC1R variants increase melanoma risk in families with CDKN2A mutations

T2 - A meta-analysis

AU - Fargnoli, Maria Concetta

AU - Gandini, Sara

AU - Peris, Ketty

AU - Maisonneuve, Patrick

AU - Raimondi, Sara

PY - 2010/5

Y1 - 2010/5

N2 - Aim of the study: We performed a meta-analysis to assess whether MC1R variants increase the risk of melanoma in CDKN2A mutation carriers of melanoma-prone families. Methods: Data from 96 CDKN2A-positive melanoma-prone families from seven independent populations of Europe, United States and Australia were included in the analysis. Summary risk estimates were calculated by random-effect models. We explored between-study heterogeneity and publication bias. Association between MC1R variants and age at diagnosis was assessed by the non-parametric Wilcoxon test. Results: CDKN2A mutation carriers with ≥1 MC1R variant showed a double melanoma risk as compared to CDKN2A mutation carriers without MC1R variants (Summary OR; 95%CI: 2.2; 1.1-4.5). MC1R heterozygous subjects had no significantly higher melanoma risk than wild-type subjects (1.6; 0.5-5.4) while carriers of multiple MC1R variants had a more than four-times higher melanoma risk (4.6; 1.3-16.4). Carriers of red hair colour (RHC) variants showed an increased melanoma risk with a Summary OR of 3.5 (95%CI: 1.3-9.9). CDKN2A mutation carriers with MC1R variants had a statistically significant lower median age at melanoma diagnosis than CDKN2A mutation carriers with no MC1R variants (37 years versus 47 years, p-value <0.0001). Conclusion: MC1R variants significantly increase penetrance of CDKN2A mutations in melanoma-prone families, especially with respect to multiple MC1R variants and to RHC variants. A significant anticipation of melanoma diagnosis is observed in CDKN2A mutation carriers with MC1R variants.

AB - Aim of the study: We performed a meta-analysis to assess whether MC1R variants increase the risk of melanoma in CDKN2A mutation carriers of melanoma-prone families. Methods: Data from 96 CDKN2A-positive melanoma-prone families from seven independent populations of Europe, United States and Australia were included in the analysis. Summary risk estimates were calculated by random-effect models. We explored between-study heterogeneity and publication bias. Association between MC1R variants and age at diagnosis was assessed by the non-parametric Wilcoxon test. Results: CDKN2A mutation carriers with ≥1 MC1R variant showed a double melanoma risk as compared to CDKN2A mutation carriers without MC1R variants (Summary OR; 95%CI: 2.2; 1.1-4.5). MC1R heterozygous subjects had no significantly higher melanoma risk than wild-type subjects (1.6; 0.5-5.4) while carriers of multiple MC1R variants had a more than four-times higher melanoma risk (4.6; 1.3-16.4). Carriers of red hair colour (RHC) variants showed an increased melanoma risk with a Summary OR of 3.5 (95%CI: 1.3-9.9). CDKN2A mutation carriers with MC1R variants had a statistically significant lower median age at melanoma diagnosis than CDKN2A mutation carriers with no MC1R variants (37 years versus 47 years, p-value <0.0001). Conclusion: MC1R variants significantly increase penetrance of CDKN2A mutations in melanoma-prone families, especially with respect to multiple MC1R variants and to RHC variants. A significant anticipation of melanoma diagnosis is observed in CDKN2A mutation carriers with MC1R variants.

KW - Cyclin-dependent kinase inhibitor 2A

KW - Familial melanoma

KW - Genetic epidemiology

KW - Melanocortin-1-receptor

UR - http://www.scopus.com/inward/record.url?scp=77951667623&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951667623&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2010.01.027

DO - 10.1016/j.ejca.2010.01.027

M3 - Article

C2 - 20189796

AN - SCOPUS:77951667623

VL - 46

SP - 1413

EP - 1420

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 8

ER -